Balancing benefits and harms: The example of non-steroidal anti-inflammatory drugs

British Medical Journal

Volumn 329, Issue 7456, 2004, Pages 31-34

  Dieppe, Paul ^a   Bartlett, Christopher ^a   Davey, Peter ^b   Doyal, Lesley ^a   Ebrahim, Shah ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTHRALGIA; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; COST BENEFIT ANALYSIS; DATA BASE; DRUG MONITORING; DRUG SAFETY; DRUG SELECTIVITY; DYSPEPSIA; FEMALE; GASTROINTESTINAL DISEASE; HIGH RISK POPULATION; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OSTEOARTHRITIS; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT; TREATMENT OUTCOME; VALIDA; VALIDATION PROCESS;

EID: 3042720639     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.329.7456.31     Document Type: Review

References (27)

1. Lawrence R, Helmick CG, Arnett FC, Deyo RA, Felson DT, Gianni EH, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-99.
2. Chard J, Tallon D, Dieppe P. Epidemiology of research into interventions for the treatment of osteoarthritis of the knee joint. Ann Rheum Dis 2000;59:414-8.
3. Evans JM, McDevitt DG, MacDonald TM. The Tayside Medicines Monitoring Unit (MEMO): a record-linkage system for pharmacovigilance. Pharmceut Med 2000;9:177-84.
4. Bartlett C, Doyal L, Ebrahim S, Davey P, Bachmann M, Egger M, et al. The causes and effects of socio-demographic exclusions from clinical trials. Health Technol Assess Rep (in press).
5. Bugeja G, Kumar A, Banarjee A. Exclusion of older people from clinical trials: a descriptive study of published reports. BMJ 1997;315:1059.
6. Bandyopadhyay S, Bayer AJ, O'Mahonoy M. Age and gender bias in statin trials. Q J Med 2001;94:127-32.
7. Nazroo J. Genetic, cultural or socio-economic vulnerability? Explaining ethnic inequalities in health. Social Health Illness 1998;20:710-30.
8. Chard J, Dickson J, Tallon D, Dieppe P. A comparison of the views of rheumatologists, general practitioners and patients on the treatment of osteoarthritis. Rheumatology 2002;41:1208-10.
9. Henry D, Lim L, Garcia Rodriguez L, Perez Gutthann S, Carson Griffin M, Savage R, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996;312:1563-6.
10. Langman S. Adverse effects of conventional non-steroidal anti-inflammatory drugs on the upper gastrointestinal tract. Fundam Clin Pharmacol 2003;17:393-403.
11. Burry H, Dieppe P, Bresnihan F, Brown C. Salicylates and renal function in rheumatoid arthritis. BMJ 1976;i:613-5.
12. Clive D, Stoff J. Renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1984;310:563-72.
13. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an unrecognised public health problem. Arch Intern Med 2000;160:777-84.
14. Wagner EH. Nonsteroidal anti-inflammatory drugs and renal disease - still unsettled. Ann Intern Med 1991;115:227-8.
15. Sandler DP, Burr FR, Weinberg CR. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med 1991;115:165-72.
16. Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med 1994;331:1675-9.
17. Evans JM, McGregor E, McMahon AD, McGilchrist MM, Jones MC, White G, et al. Non-steroidal anti-inflammatory drugs and hospitalisation for acute renal failure. Q J Med 1995;88:551-7.
18. Perez Gutthann S, Garcia Rodriguez LA, Raiford DS, Duque Oliart Ris Romeu J. Nonsteroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure. Arch Intern Med 1996;156:2433-9.
19. Kargman S, Charleson S, Cartwright M, Frank J, Riendeau D, Mandle J, et al. Characterisation of prostaglandin G/H synthetase 1 and 2 in rat, dog, monkey and human gastrointestinal tracts. Gastroenterology 1996;111:445-54.
20. Mukherjee D, Nissen S, Topol E. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9.
21. Juni P, Dieppe P, Egger M. Risk of myocardial infarction associated with selective COX-inhibitors: questions remain. Arch Intern Med 2002;162:2639-40.
22. Huong DL, Papo T, Beaufils H, Wechsler B, Bletroy O, Baumelou A, et al. Renal involvement in systemic lupus erythematosus: a study of 180 patients from a single centre. Medicine (Baltimore) 1999;78:148-66.
23. Helin HJ, Korpola MM, Mustonen JT, Pasternack AI. Renal biopsy findings and clinicopathological correlations in rheumatoid arthritis. Arthritis Rheum 1995;38:242-7.
24. Furst D. Clinically important interactions of non-steroidal anti-inflammatory drugs with other medications. J Rheumatol 1988;17(suppl):58- 62.
25. Al Shahi R, Warlow C. Using patient-identifiable data for observational research and audit. BMJ 2000;321:1031-2.
26. Holman CD. The impracticable nature of consent for research use of linked administrative health records. Aust NZ J Public Health 2001;25:421-2.
27. West of Scotland Coronary Prevention Study Group. Computerised record linkage: compared with traditional patient follow-up methods in clinical trials and illustrated in a prospective epidemiological study. J Clin Epidemiol 1995;48:1441-52.